| Natarajan Asokan, MD | |
|
3931 Stockton Hill Rd, Suite D, Kingman, AZ 86409-2426 | |
| (928) 681-5800 | |
| (928) 681-5801 |
| Full Name | Natarajan Asokan |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 42 Years |
| Location | 3931 Stockton Hill Rd, Kingman, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649248725 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 23270 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kingman Regional Medical Center | Kingman, AZ | Hospital |
| Western Arizona Regional Medical Center | Bullhead city, AZ | Hospital |
| Valley View Medical Center | Fort mohave, AZ | Hospital |
| Entity Name | Trinity Allergy Asthma And Immunology Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265550321 PECOS PAC ID: 8224139985 Enrollment ID: O20070725000003 |
News Archive
Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.
Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.
New research led by Plymouth University Peninsula Schools of Medicine and Dentistry suggests that the cognitive test used in Alzheimer's drug trials is flawed.
When researchers sequence the RNA of cancer cells, they can compare it to normal cells and see where there is more RNA. That can help lead them to the gene or protein that might be triggering the cancer.
Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Natarajan Asokan, MD 3931 Stockton Hill Rd, Suite D, Kingman, AZ 86409-2426 Ph: (928) 681-5800 | Natarajan Asokan, MD 3931 Stockton Hill Rd, Suite D, Kingman, AZ 86409-2426 Ph: (928) 681-5800 |
News Archive
Five Prime Therapeutics, Inc., a leader in the discovery and development of innovative biologics, and Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, today announced an alliance to fund the development of a FivePrime pre-clinical stage therapeutic candidate for treatment of Multiple Sclerosis (MS). Fast Forward will commit up to $1 million to fund the advancement of the therapeutic candidate.
Santarus, Inc. and Depomed, Inc. today announced that they have entered into a new commercialization agreement for GLUMETZA (metformin hydrochloride extended release tablets) under which Santarus will assume broad commercial, manufacturing and regulatory responsibilities to replace a promotion agreement that the companies entered into in July 2008.
New research led by Plymouth University Peninsula Schools of Medicine and Dentistry suggests that the cognitive test used in Alzheimer's drug trials is flawed.
When researchers sequence the RNA of cancer cells, they can compare it to normal cells and see where there is more RNA. That can help lead them to the gene or protein that might be triggering the cancer.
Intra-Cellular Therapies, Inc. ("ITI") and Takeda Pharmaceutical Company Limited, today announced that they have entered into an exclusive collaboration to develop and commercialize selective phosphodiesterase type 1 (PDE1) inhibitors, discovered by ITI, for the treatment of cognitive impairment associated with schizophrenia. This agreement is targeted worldwide, but ITI has retained the option to co-promote with Takeda in the United States.
› Verified 6 days ago